• Home
  • Pharmaceuticals and Healthcare
Liposomal and Lipid-based Nanoparticle Drug Market - Global Outlook and Forecast 2021-2027

Liposomal and Lipid-based Nanoparticle Drug Market - Global Outlook and Forecast 2021-2027

Report Code: KNJ759043 | No. of Pages: 112 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Jun-2021 
The Liposomal and Lipid-based Nanoparticle Drug market report provides the overall market analysis of the industry. This market report presents the current snapshot of the Liposomal and Lipid-based Nanoparticle Drug market to understand the market's key features. The content of the report highlights the important market criteria that help to develop the market further. The report provides the value and the volume of the Liposomal and Lipid-based Nanoparticle Drug at global, regional, and company levels. The historical market value for the year 2021 along with the market value for the upcoming year 2027 has been presented in the market report. Along with that, the report also provides information on subjects such as Export, import, production, and production capacity of the Liposomal and Lipid-based Nanoparticle Drug market.This report contains market size and forecasts of Liposomal and Lipid-based Nanoparticle Drug in Global, including the following market information:
Global Liposomal and Lipid-based Nanoparticle Drug Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global top five companies in 2020 (%)
The global Liposomal and Lipid-based Nanoparticle Drug market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Liposomal and Lipid-based Nanoparticle Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Liposomal and Lipid-based Nanoparticle Drug Market, By Type, 2016-2021, 2022-2027 ($ millions)
Global Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, By Type, 2020 (%)
Liposomes Drugs
Lipid Nanoparticle Drugs

China Liposomal and Lipid-based Nanoparticle Drug Market, By Application, 2016-2021, 2022-2027 ($ millions)
China Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, By Application, 2020 (%)
Hospital
Retail Pharmacy
Other

Global Liposomal and Lipid-based Nanoparticle Drug Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)
Global Liposomal and Lipid-based Nanoparticle Drug Market Segment Percentages, By Region and Country, 2020 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Total Liposomal and Lipid-based Nanoparticle Drug Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)
Total Liposomal and Lipid-based Nanoparticle Drug Market Competitors Revenues Share in Global, by Players 2020 (%)
Further, the report presents profiles of competitors in the market, including the following:
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
1 Introduction to Research & Analysis Reports
    1.1 Liposomal and Lipid-based Nanoparticle Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Liposomal and Lipid-based Nanoparticle Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Liposomal and Lipid-based Nanoparticle Drug Overall Market Size
    2.1 Global Liposomal and Lipid-based Nanoparticle Drug Market Size: 2021 VS 2027
    2.2 Global Liposomal and Lipid-based Nanoparticle Drug Market Size, Prospects & Forecasts: 2016-2027
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Liposomal and Lipid-based Nanoparticle Drug Players in Global Market
    3.2 Top Global Liposomal and Lipid-based Nanoparticle Drug Companies Ranked by Revenue
    3.3 Global Liposomal and Lipid-based Nanoparticle Drug Revenue by Companies
    3.4 Top 3 and Top 5 Liposomal and Lipid-based Nanoparticle Drug Companies in Global Market, by Revenue in 2020
    3.5 Global Companies Liposomal and Lipid-based Nanoparticle Drug Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Liposomal and Lipid-based Nanoparticle Drug Players in Global Market
        3.6.1 List of Global Tier 1 Liposomal and Lipid-based Nanoparticle Drug Companies
        3.6.2 List of Global Tier 2 and Tier 3 Liposomal and Lipid-based Nanoparticle Drug Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Market Size Markets, 2021 & 2027
        4.1.2 Liposomes Drugs
        4.1.3 Lipid Nanoparticle Drugs
    4.2 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts
        4.2.1 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2021
        4.2.2 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2022-2027
        4.2.3 By Type - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2016-2027
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Market Size, 2021 & 2027
        5.1.2 Hospital
        5.1.3 Retail Pharmacy
        5.1.4 Other
    5.2 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts
        5.2.1 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2021
        5.2.2 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2022-2027
        5.2.3 By Application - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2016-2027
6 Sights by Region
    6.1 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Market Size, 2021 & 2027
    6.2 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue & Forecasts
        6.2.1 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2021
        6.2.2 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue, 2022-2027
        6.2.3 By Region - Global Liposomal and Lipid-based Nanoparticle Drug Revenue Market Share, 2016-2027
    6.3 North America
        6.3.1 By Country - North America Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2027
        6.3.2 US Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.3.3 Canada Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.3.4 Mexico Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
    6.4 Europe
        6.4.1 By Country - Europe Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2027
        6.4.2 Germany Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.3 France Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.4 U.K. Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.5 Italy Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.6 Russia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.7 Nordic Countries Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.4.8 Benelux Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
    6.5 Asia
        6.5.1 By Region - Asia Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2027
        6.5.2 China Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.5.3 Japan Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.5.4 South Korea Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.5.5 Southeast Asia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.5.6 India Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
    6.6 South America
        6.6.1 By Country - South America Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2027
        6.6.2 Brazil Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.6.3 Argentina Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Liposomal and Lipid-based Nanoparticle Drug Revenue, 2016-2027
        6.7.2 Turkey Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.7.3 Israel Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.7.4 Saudi Arabia Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
        6.7.5 UAE Liposomal and Lipid-based Nanoparticle Drug Market Size, 2016-2027
7 Players Profiles
    7.1 Johnson & Johnson
        7.1.1 Johnson & Johnson Corporate Summary
        7.1.2 Johnson & Johnson Business Overview
        7.1.3 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.1.4 Johnson & Johnson Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.1.5 Johnson & Johnson Key News
    7.2 Sun Pharmaceutical
        7.2.1 Sun Pharmaceutical Corporate Summary
        7.2.2 Sun Pharmaceutical Business Overview
        7.2.3 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.2.4 Sun Pharmaceutical Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.2.5 Sun Pharmaceutical Key News
    7.3 CSPC
        7.3.1 CSPC Corporate Summary
        7.3.2 CSPC Business Overview
        7.3.3 CSPC Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.3.4 CSPC Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.3.5 CSPC Key News
    7.4 Kinyond
        7.4.1 Kinyond Corporate Summary
        7.4.2 Kinyond Business Overview
        7.4.3 Kinyond Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.4.4 Kinyond Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.4.5 Kinyond Key News
    7.5 Teva
        7.5.1 Teva Corporate Summary
        7.5.2 Teva Business Overview
        7.5.3 Teva Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.5.4 Teva Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.5.5 Teva Key News
    7.6 Fudan-Zhangjiang
        7.6.1 Fudan-Zhangjiang Corporate Summary
        7.6.2 Fudan-Zhangjiang Business Overview
        7.6.3 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.6.4 Fudan-Zhangjiang Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.6.5 Fudan-Zhangjiang Key News
    7.7 Zydus Cadila
        7.7.1 Zydus Cadila Corporate Summary
        7.7.2 Zydus Cadila Business Overview
        7.7.3 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.4.4 Zydus Cadila Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.7.5 Zydus Cadila Key News
    7.8 TTY Biopharma
        7.8.1 TTY Biopharma Corporate Summary
        7.8.2 TTY Biopharma Business Overview
        7.8.3 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.8.4 TTY Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.8.5 TTY Biopharma Key News
    7.9 Pacira
        7.9.1 Pacira Corporate Summary
        7.9.2 Pacira Business Overview
        7.9.3 Pacira Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.9.4 Pacira Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.9.5 Pacira Key News
    7.10 Luye Pharma
        7.10.1 Luye Pharma Corporate Summary
        7.10.2 Luye Pharma Business Overview
        7.10.3 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.10.4 Luye Pharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.10.5 Luye Pharma Key News
    7.11 Leadiant Biosciences
        7.11.1 Leadiant Biosciences Corporate Summary
        7.11.2 Leadiant Biosciences Business Overview
        7.11.3 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.11.4 Leadiant Biosciences Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.11.5 Leadiant Biosciences Key News
    7.12 Ipsen
        7.12.1 Ipsen Corporate Summary
        7.12.2 Ipsen Business Overview
        7.12.3 Ipsen Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.12.4 Ipsen Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.12.5 Ipsen Key News
    7.13 Sayre Therapeutics
        7.13.1 Sayre Therapeutics Corporate Summary
        7.13.2 Sayre Therapeutics Business Overview
        7.13.3 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.13.4 Sayre Therapeutics Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.13.5 Sayre Therapeutics Key News
    7.14 Jazz
        7.14.1 Jazz Corporate Summary
        7.14.2 Jazz Business Overview
        7.14.3 Jazz Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.14.4 Jazz Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.14.5 Jazz Key News
    7.15 Alnylam
        7.15.1 Alnylam Corporate Summary
        7.15.2 Alnylam Business Overview
        7.15.3 Alnylam Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.15.4 Alnylam Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.15.5 Alnylam Key News
    7.16 Bausch Health
        7.16.1 Bausch Health Corporate Summary
        7.16.2 Bausch Health Business Overview
        7.16.3 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.16.4 Bausch Health Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.16.5 Bausch Health Key News
    7.17 Acrotech Biopharma
        7.17.1 Acrotech Biopharma Corporate Summary
        7.17.2 Acrotech Biopharma Business Overview
        7.17.3 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.17.4 Acrotech Biopharma Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.17.5 Acrotech Biopharma Key News
    7.18 Takeda
        7.18.1 Takeda Corporate Summary
        7.18.2 Takeda Business Overview
        7.18.3 Takeda Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.18.4 Takeda Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.18.5 Takeda Key News
    7.19 Chiesi Farmaceutici
        7.19.1 Chiesi Farmaceutici Corporate Summary
        7.19.2 Chiesi Farmaceutici Business Overview
        7.19.3 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.19.4 Chiesi Farmaceutici Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.19.5 Chiesi Farmaceutici Key News
    7.20 Gilead Sciences
        7.20.1 Gilead Sciences Corporate Summary
        7.20.2 Gilead Sciences Business Overview
        7.20.3 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Major Product Offerings
        7.20.4 Gilead Sciences Liposomal and Lipid-based Nanoparticle Drug Revenue in Global (2016-2021)
        7.20.5 Gilead Sciences Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

NEED Help?

If you need any help or guidance, please feel free to call us.

USA : +1 (661) 636 6162

INDIA : +91 9325802062

or

Write us on : sales@kandjmarketresearch.com